Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)
29.20
-0.05 (-0.17%)
At close: Mar 27, 2026
TPEX:4111 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 443.91 | 336.19 | 381.05 | 456.25 | 252.27 |
Cash & Short-Term Investments | 443.91 | 336.19 | 381.05 | 456.25 | 252.27 |
Cash Growth | 32.04% | -11.77% | -16.48% | 80.86% | -24.88% |
Accounts Receivable | 352.14 | 326.5 | 309.71 | 282.64 | 281.4 |
Other Receivables | 6.23 | 18.58 | 19.94 | 0.66 | 0.81 |
Receivables | 358.37 | 345.07 | 329.65 | 283.3 | 282.2 |
Inventory | 103.38 | 96.85 | 89.17 | 99.03 | 90.25 |
Prepaid Expenses | 8.05 | 6.49 | 4.11 | 2.23 | 9.92 |
Other Current Assets | 11.41 | 0.02 | 0.02 | 16.82 | 16.83 |
Total Current Assets | 925.12 | 784.62 | 804 | 857.64 | 651.47 |
Property, Plant & Equipment | 764.99 | 756.98 | 720.35 | 785.33 | 899.42 |
Long-Term Investments | 1.81 | 1.81 | 1.84 | 3.48 | 3.97 |
Other Intangible Assets | 1.41 | 1.63 | 1.46 | 1.04 | 0.9 |
Long-Term Deferred Tax Assets | 6.61 | 11.23 | 35.54 | 54.2 | 6.1 |
Other Long-Term Assets | 237.84 | 193.37 | 202.92 | 98.84 | 97.92 |
Total Assets | 1,938 | 1,750 | 1,766 | 1,801 | 1,660 |
Accounts Payable | 223.41 | 240.28 | 226.33 | 237.03 | 205.74 |
Short-Term Debt | 10 | 10 | 120 | 120 | 130 |
Current Portion of Leases | 7.47 | 9.53 | 2.12 | 6.11 | 6.72 |
Current Income Taxes Payable | 39.1 | 1 | 1.2 | 18.7 | 14.01 |
Current Unearned Revenue | 0.01 | 0.14 | 1.17 | 4.77 | 7.79 |
Other Current Liabilities | 181.01 | 111.85 | 100.63 | 95.29 | 82.63 |
Total Current Liabilities | 461 | 372.8 | 451.46 | 481.89 | 446.88 |
Long-Term Leases | 6.43 | 7.09 | 0.78 | 2.28 | 7.28 |
Pension & Post-Retirement Benefits | - | 8.89 | 11.24 | 9.08 | 18.61 |
Long-Term Deferred Tax Liabilities | 78.67 | 79.94 | 76.52 | 77.85 | 76.52 |
Other Long-Term Liabilities | 10.95 | 6.35 | 7.05 | 7.29 | 9.75 |
Total Liabilities | 557.04 | 475.08 | 547.04 | 578.38 | 559.04 |
Common Stock | 598.32 | 569.83 | 569.83 | 569.83 | 569.83 |
Additional Paid-In Capital | 48.85 | 48.85 | 48.85 | 48.85 | 48.85 |
Retained Earnings | 736.4 | 658.71 | 603.19 | 604.63 | 506.39 |
Comprehensive Income & Other | -2.84 | -2.84 | -2.8 | -1.16 | -24.33 |
Shareholders' Equity | 1,381 | 1,275 | 1,219 | 1,222 | 1,101 |
Total Liabilities & Equity | 1,938 | 1,750 | 1,766 | 1,801 | 1,660 |
Total Debt | 23.9 | 26.62 | 122.9 | 128.38 | 144 |
Net Cash (Debt) | 420.01 | 309.57 | 258.15 | 327.87 | 108.27 |
Net Cash Growth | 35.68% | 19.92% | -21.26% | 202.84% | -66.51% |
Net Cash Per Share | 6.95 | 5.15 | 4.30 | 5.45 | 1.80 |
Filing Date Shares Outstanding | 59.46 | 59.83 | 59.83 | 59.83 | 59.83 |
Total Common Shares Outstanding | 59.46 | 59.83 | 59.83 | 59.83 | 59.83 |
Working Capital | 464.12 | 411.82 | 352.54 | 375.74 | 204.59 |
Book Value Per Share | 23.22 | 21.30 | 20.37 | 20.43 | 18.40 |
Tangible Book Value | 1,379 | 1,273 | 1,218 | 1,221 | 1,100 |
Tangible Book Value Per Share | 23.20 | 21.27 | 20.35 | 20.41 | 18.38 |
Land | - | 371.9 | 371.9 | 478.28 | 478.28 |
Buildings | - | 662.04 | 636.77 | 538.78 | 703.06 |
Machinery | - | 585.74 | 549.8 | 529.11 | 569.08 |
Construction In Progress | - | 36.28 | 30.51 | 82.48 | 2.96 |
Leasehold Improvements | - | 2.44 | 2.29 | 3.41 | 3.41 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.